

Princy N Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5264712/publications.pdf>

Version: 2024-02-01

59
papers

2,723
citations

566801

15
h-index

264894

42
g-index

60
all docs

60
docs citations

60
times ranked

4310
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 632.	3.8	803
2	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1382-1392.	13.9	534
3	Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease. <i>Annals of Internal Medicine</i> , 2001, 135, 17.	2.0	516
4	Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. <i>New England Journal of Medicine</i> , 2018, 379, 645-654.	13.9	162
5	Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection in Patients at Increased Risk for Recurrence. <i>Clinical Infectious Diseases</i> , 2018, 67, 649-656.	2.9	143
6	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. <i>Lancet HIV</i> , the, 2020, 7, e740-e751.	2.1	58
7	A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. <i>Clinical Infectious Diseases</i> , 2022, 75, e440-e449.	2.9	46
8	Persistent Oxidative Stress and Inflammasome Activation in CD14 ^{high} CD16a ^{hi} Monocytes From COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 799558.	2.2	44
9	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. <i>Clinical Infectious Diseases</i> , 2016, 63, 836-843.	2.9	37
10	Bartonella Endocarditis and Pauci-Immune Glomerulonephritis. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 254-260.	0.1	35
11	The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 636-647.	0.5	34
12	Evolocumab in HIV-Infected Patients With Dyslipidemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2570-2584.	1.2	30
13	Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 801-805.	0.9	25
14	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab537.	0.4	19
15	A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). <i>AIDS Research and Therapy</i> , 2009, 6, 3.	0.7	18
16	Low CD4 nadir linked to widespread cortical thinning in adults living with HIV. <i>NeuroImage: Clinical</i> , 2020, 25, 102155.	1.4	18
17	Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 86-95.	0.9	15
18	Safety and Efficacy of Tocilizumab 4 or 8Âmg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab608.	0.4	14

#	ARTICLE	IF	CITATIONS
19	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 268-280.	2.9	13
20	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. <i>Aids</i> , 2021, 35, 1061-1072.	1.0	13
21	Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 815833.	2.2	11
22	Depression is associated with hippocampal volume loss in adults with HIV. <i>Human Brain Mapping</i> , 2021, 42, 3750-3759.	1.9	9
23	Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. <i>Journal of Community Health</i> , 2021, 46, 75-85.	1.9	9
24	“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. <i>Culture, Health and Sexuality</i> , 2020, 23, 1-13.	1.0	8
25	IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells. <i>IScience</i> , 2022, 25, 103588.	1.9	8
26	Connectome-based prediction of global cognitive performance in people with HIV. <i>NeuroImage: Clinical</i> , 2021, 30, 102677.	1.4	7
27	Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHT Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0175121.	1.4	7
28	Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. <i>American Heart Journal</i> , 2020, 220, 203-212.	1.2	6
29	Comorbidity and comedication burden among people living with HIV in the United States. <i>Current Medical Research and Opinion</i> , 2022, 38, 1443-1450.	0.9	6
30	Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1. <i>Open Forum Infectious Diseases</i> , 2017, 4, S38-S39.	0.4	5
31	A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE). <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz246.	0.4	5
32	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
33	1060. Pritelivir in Immunocompromised Patients with Mucocutaneous Acyclovir-Resistant Herpes Simplex Virus-Infections – First Case Series. <i>Open Forum Infectious Diseases</i> , 2021, 8, S622-S623.	0.4	3
34	The impacts of HIV infection, age, and education on functional brain networks in adults with HIV. <i>Journal of NeuroVirology</i> , 2022, 28, 265-273.	1.0	3
35	2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences. <i>Open Forum Infectious Diseases</i> , 2019, 6, S866-S866.	0.4	2
36	A disease disregards anatomical planes: actinomycosis and an intrauterine device. <i>Lancet, The</i> , 2020, 396, 1766.	6.3	2

#	ARTICLE	IF	CITATIONS
37	The Cost-Effectiveness and Budget Impact of Ibalizumab-uyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States. <i>Pharmacoeconomics</i> , 2021, 39, 421-432.	1.7	2
38	Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab338.	0.4	2
39	639. Time to Recurrence of <i>Clostridioides difficile</i> Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic. <i>Open Forum Infectious Diseases</i> , 2021, 8, S422-S422.	0.4	2
40	544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S202-S202.	0.4	1
41	Healthcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection. <i>Neurohospitalist, The</i> , 2020, 12, 194187442096684.	0.3	1
42	The Role of Inflammation and Immune Activation on Circulating Endothelial Progenitor Cells in Chronic HIV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 663412.	2.2	1
43	IL-27 Modulates the Cytokine Secretion in the T Cellâ€‘Osteoclast Crosstalk During HIV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 818677.	2.2	1
44	Prevalence of Multidrug-Resistant Organisms Using an Antibiotic Resistant Gene Assay at a Tertiary Care Center. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
45	Assessing Carbapenemase Resistant Enterobacteriaceae Prevalence Using a Combined Antibiotic Resistance Gene Assay and Surveillance Cultures in Hospitalized Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
46	Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
47	[ICâ€‘46]: TASKâ€‘FREE MAGNETIC RESONANCE BRAIN IMAGING DISTINGUISHES ALZHEIMER'S DISEASE FROM HIVâ€‘DISEASE VIA SUPPORT VECTOR MACHINE CLASSIFICATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P111.	0.4	0
48	[P1â€‘373]: TASKâ€‘FREE MAGNETIC RESONANCE BRAIN IMAGING DISTINGUISHES ALZHEIMER'S DISEASE FROM HIVâ€‘DISEASE VIA SUPPORT VECTOR MACHINE CLASSIFICATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P404.	0.4	0
49	2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S864-S865.	0.4	0
50	2786. The Role of Respiratory Panel PCR in Decreasing Antibiotic Exposure in Patients Diagnosed With a Respiratory Viral Infection. <i>Open Forum Infectious Diseases</i> , 2019, 6, S984-S984.	0.4	0
51	41224 REDUCED FRONTOSTRIATAL FUNCTIONAL CONNECTIVITY IN 41- TO 70-YEAR-OLD ADULTS WITH HIV. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 13-13.	0.3	0
52	1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311). <i>Open Forum Infectious Diseases</i> , 2020, 7, S532-S532.	0.4	0
53	1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, S552-S553.	0.4	0
54	466. SARS-CoV-2 Diagnosis And Point Prevalence in a Non-Cohorted Tertiary Care Center. <i>Open Forum Infectious Diseases</i> , 2020, 7, S299-S300.	0.4	0

#	ARTICLE	IF	CITATIONS
55	509. Clinical Characteristics and Outcomes in Patients Infected with SARS-CoV-2 Treated with Remdesivir, Tocilizumab, and/or Dexamethasone at a Mid-Atlantic Hospital Consortium. Open Forum Infectious Diseases, 2021, 8, S356-S357.	0.4	0
56	832. Body Mass Index and Quality of Life in People Living With HIV. Open Forum Infectious Diseases, 2021, 8, S508-S508.	0.4	0
57	297. Infectious Complications Associated with Tocilizumab Use in Patients Infected with SARS-CoV-2 at a Mid-Atlantic Hospital Consortium. Open Forum Infectious Diseases, 2021, 8, S256-S256.	0.4	0
58	286. Infectious Complications and Antimicrobial Utilization in Hospitalized Patients with COVID-19. Open Forum Infectious Diseases, 2021, 8, S249-S249.	0.4	0
59	Cingulate transcranial direct current stimulation in adults with HIV. PLoS ONE, 2022, 17, e0269491.	1.1	0